Intel stock spikes after report of possible US government stake
Investing.com - Cantor Fitzgerald has reiterated its Overweight rating and $4.00 price target on Cerus (NASDAQ:CERS), currently trading at $1.21, following the company’s second-quarter 2025 financial results. According to InvestingPro data, the company maintains a healthy gross profit margin of 56.1% despite challenging market conditions.
Cerus reported product revenue of $52.4 million for the second quarter, exceeding both Cantor Fitzgerald’s estimate of $49.5 million and the FactSet consensus of $48.0 million. This represents year-over-year growth of approximately 16%, driven by increased sales in Intercept Fibrinogen Complex (IFC) and global platelet products. The company’s trailing twelve-month revenue stands at $192.5M, with a consistent revenue CAGR of 19% over the past five years.
The company has increased its 2025 product revenue guidance following these strong quarterly results. On the product development front, Cerus’s INT200 device has now received regulatory approval in approximately 40 countries, with customers reportedly valuing its operational efficiency and user-friendly design.
Cerus also announced it has been awarded an additional $7.2 million from the Department of Defense (DoD) to support CRYO-FIRST, a randomized study comparing lyophilized IFC to conventional CRYO-AFH in trauma-associated hemorrhagic shock patients.
The financial results were reported on August 5, 2025, with Cantor Fitzgerald maintaining its positive outlook on the blood safety technology company’s stock.
In other recent news, Cerus Corporation reported its Q2 2025 earnings, revealing a revenue of $60.1 million, which exceeded the forecasted $54.37 million. The company met earnings per share expectations, posting a result of -$0.03. Despite these results, the stock experienced fluctuations during trading sessions. These developments are part of a series of recent updates concerning Cerus Corporation. Investors and analysts are closely monitoring the company’s financial performance. The earnings report highlights Cerus Corporation’s ability to surpass revenue projections. These results are crucial for stakeholders evaluating the company’s financial health.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.